Previous 10 | Next 10 |
Image source: The Motley Fool. Corcept Therapeutics Incorporated (NASDAQ: CORT) Q4 2020 Earnings Call Feb 8, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings ...
Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Conference Call February 8, 2021 5:00 PM ET Company Participants Charlie Robb – Chief Financial Officer Joseph Belanoff – Chief Executive Officer Sean Maduck – Chief Commercial Officer Andreas Grauer – Chief...
Financial Highlights, 2021 Revenue Guidance and Legal Update Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019 Preliminary fourth quarter revenue $85.7 million, compared to $87.9 million in fourth quarter 2019 2021 revenue guidance $37...
MENLO PARK, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results and provide a corporate update on February 8, 2021. The company will host a conference ca...
MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone...
Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%,...
Phoenix New Media (FENG) +62% after announcing special distribution.Hudson Capital (HUSN) +37%.Aptevo Therapeutics (APVO) +31% following a disclosure that 42.5% shareholder Tang Capital Partners offered to buy the remaining shares for $50/share in cash.Corcept Therapeutics...
MENLO PARK, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone...
Corcept Therapeautics (CORT) +23.8% after-hours following news of a favorable ruling in Teva Pharmaceuticals' (TEVA) challenge of its Korlym Label patent for Korlym, which is used to treat Cushing's disease.The U.S. Patent Trial and Appeal Board upheld Corcept's patent, saying Teva "has not s...
Corcept Therapeutics Incorporated (CORT) Q3 2020 Earnings Conference Call November 03, 2020 5:00 PM ET Company Participants Conference Call Participants Presentation Operator Good day, and welcome to the Corcept Therapeutics Conference Call. Today's call is being recorded. [Operator Instructi...
News, Short Squeeze, Breakout and More Instantly...
Corcept Therapeutics Incorporated Company Name:
CORT Stock Symbol:
NASDAQ Market:
2024-05-02 17:30:02 ET Truist Financial analyst issues BUY recommendation for CORT on May 2, 2024 04:01PM ET. The previous analyst recommendation was Buy. CORT was trading at $25.06 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of th...